177
0 Kommentare
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500
177 
0 KommentareVir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first for the second year in a row on the 2023 Deloitte Technology Fast 500, a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America. This is the first time in the 29-year history of the Deloitte Technology Fast 500 program that a company has topped the list for two consecutive years.
The Company’s revenue growth between fiscal years 2019 and 2022 was fueled by global sales of sotrovimab (Xevudy), an investigational SARS-CoV-2 neutralizing monoclonal antibody, and was recognized in conjunction with Vir’s collaboration partner GSK, as well as additional contract, licensing and grant agreements with GSK and others, including Brii Biosciences and the Bill & Melinda Gates Foundation.
“Ranking number one for the second year in a row on the Deloitte Technology Fast 500 list reflects Vir’s ability to leverage our world class immunology expertise to engineer human antibodies into very powerful medicines,” said Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer. “This growth success is fueling our clinical programs while also strengthening our scientific platforms and pipeline so we can continue to power the immune system to transform lives.”
About the 2023 Deloitte Technology Fast 500
Now in its 29th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies – both public and private – in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2019 to 2022.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.
About Sotrovimab
Lesen Sie auch
Sotrovimab is an investigational SARS-CoV-2 neutralizing monoclonal antibody that was developed in collaboration with GSK. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS). Sotrovimab, which incorporates Xencor, Inc.’s Xtend technology, has been designed to achieve high concentration in the lungs to achieve optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life. Sotrovimab was identified using Vir’s proprietary mAb discovery platform. Sotrovimab is currently not authorized in the US.
Aktuelle Themen
Weitere Artikel des Autors
URL kopieren
Per E-Mail teilen
Artikel drucken
Artikel zu den Werten
Auch bei Lesern beliebt
